Sonnet biotherapeutics expands phase 1 sb101 trial to evaluate combination of son-1010 with trabectedin in certain sarcomas

Son-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (yondelis ® ) with the potential to improve trabectedin's therapeutic window in soft-tissue sarcoma patients
SONN Ratings Summary
SONN Quant Ranking